---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-26-000042"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2026-07-30T20:18:32+00:00"
generated_at: "2026-07-30T20:19:16.906309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q2 revenue up 15% to $150.3M; launches Prosigna and TrueMRD

## Summary
- Total revenue $150.3M (+15% YoY); testing revenue $145.7M (+19%); Decipher +20%, Afirma +18%.
- GAAP net income $25.5M (17% of revenue); adjusted EBITDA $44.0M (29.2% of revenue).
- Launched Prosigna LDT for early-stage HR+ breast cancer and TrueMRD for MIBC; secured Medicare coverage for TrueMRD.
- Cash from ops $45.8M; cash & investments $485.2M as of June 30, 2026.
- Total testing volume up 14% to 48,389 tests; Decipher tests +17%, Afirma +10%.

## SEC filing metadata
- accession: 0001384101-26-000042
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2026-07-30T20:18:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/0001384101-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/vcyt-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-26-000042
- JSON: https://secwatch.observer/filing/0001384101-26-000042.json
- Plain text: https://secwatch.observer/filing/0001384101-26-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.